<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30405611</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1664-3224</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in immunology</Title>                <ISOAbbreviation>Front Immunol</ISOAbbreviation>            </Journal>            <ArticleTitle>Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia.</ArticleTitle>            <Pagination>                <MedlinePgn>2408</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2018.02408</ELocationID>            <Abstract>                <AbstractText>Despite the constant development of innovative therapeutic options for hematological malignancies, the gold-standard therapy regimen for curative treatment often includes allogeneic hematopoietic stem cell transplantation (HSCT). The graft-vs.-leukemia effect (GVL) is one of the main therapeutic goals that arises from HSCT. On the other hand, graft-vs.-host disease (GVHD) is still one of the main and most serious complications following allogeneic HSCT. In acute myeloid leukemia (AML), HSCT together with high-dose chemotherapy is used as a treatment option. An aggressive progression of the disease, a decreased response to treatment, and a poor prognosis are connected to internal tandem duplication (ITD) mutations in the Fms like tyrosine kinase 3 (FLT3) gene, which affects around 30% of AML patients. In this study, C3H/HeN mice received an allogeneic graft together with 32D-FLT3<sup>ITD</sup> AML cells to induce acute GVHD and GVL. It was examined if pre-incubation of the graft with the anti-human cluster of differentiation (CD) 4 antibody MAX.16H5 IgG<sub>1</sub> prevented the development of GVHD and whether the graft function was impaired. Animals receiving grafts pre-incubated with the antibody together with FLT3<sup>ITD</sup> AML cells survived significantly longer than mice receiving untreated grafts. The observed prolonged survival due to MAX.16H5 incubation of immune cell grafts prior to transplantation may allow an extended application of additional targeted strategies in the treatment of AML.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hilger</LastName>                    <ForeName>Nadja</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute for Clinical Immunology, University of Leipzig, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mueller</LastName>                    <ForeName>Claudia</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stahl</LastName>                    <ForeName>Lilly</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mueller</LastName>                    <ForeName>Anne M</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zoennchen</LastName>                    <ForeName>Bianca</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dluczek</LastName>                    <ForeName>Sarah</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Halbich</LastName>                    <ForeName>Christoph</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wickenhauser</LastName>                    <ForeName>Claudia</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Pathology, Halle University Hospital, Halle, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gerloff</LastName>                    <ForeName>Dennis</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Dermatology and Venereology, University Hospital Halle, Halle, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wurm</LastName>                    <ForeName>Alexander A</ForeName>                    <Initials>AA</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology and Medical Oncology, Leipzig University Hospital, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Behre</LastName>                    <ForeName>Gerhard</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology and Medical Oncology, Leipzig University Hospital, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kretschmer</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fricke</LastName>                    <ForeName>Stephan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Immune Tolerance, Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>22</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Immunol</MedlineTA>            <NlmUniqueID>101560960</NlmUniqueID>            <ISSNLinking>1664-3224</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">32D-FLT3ITD</Keyword>            <Keyword MajorTopicYN="N">C3H/HeN</Keyword>            <Keyword MajorTopicYN="N">acute myeloid leukemia</Keyword>            <Keyword MajorTopicYN="N">anti-human CD4 antibody MAX.16H5</Keyword>            <Keyword MajorTopicYN="N">graft-vs.-host disease</Keyword>            <Keyword MajorTopicYN="N">graft-vs.-leukemia</Keyword>            <Keyword MajorTopicYN="N">hematopoietic stem cell transplantation</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30405611</ArticleId>            <ArticleId IdType="doi">10.3389/fimmu.2018.02408</ArticleId>            <ArticleId IdType="pmc">PMC6204383</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>